stockportfolio.pro
Stocks / DNTH vs LIVN
DNTH vs LIVN
Dianthus Therapeutics, Inc. and LivaNova PLC side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Dianthus Therapeutics, Inc. (DNTH) | LivaNova PLC (LIVN) | |
|---|---|---|
| Market cap | $4.4B | $4.3B |
| Revenue (latest FY) | $2.04M | $1.39B |
| Net income (latest FY) | $-162.34M | $-242.50M |
| Revenue growth (5y CAGR) | — | 8.2% |
| Net margin | -7973.3% | -17.5% |
| Return on equity | -32.9% | -20.2% |
| P/E ratio | — | 39.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DNTH — free Open LIVN — freeFrequently asked questions
Which is bigger, DNTH or LIVN?
Dianthus Therapeutics, Inc. is larger by market capitalization — $4.4B versus $4.3B.
Which grows faster, DNTH or LIVN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.